Roche

Roche inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker’s shares even though more data will be needed to confirm the treatment’s efficacy.

The U.S. government said on Tuesday it had awarded $1.4 billion for the development of new therapies and vaccines against COVID-19, including a $326 million contract with Regeneron Pharmaceuticals or a next-generation antibody therapy for prevention of infections.

Novavax

Novavax Inc. said on Tuesday its updated protein-based COVID-19 vaccine generated an immune response against emerging forms of coronavirus such as the “Eris” subvariant in small studies in animals.

Pfizer

The U.S. Food and Drug Administration on Monday approved Pfizer’s (PFE.N) respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.

Moderna

Moderna and China’s CARsgen Therapeutics are collaborating to combine their respective mRNA therapeutic cancer vaccine with a solid tumor CAR T cell therapy, the Chinese biotech announced on Monday.

The FDA has established a voluntary pilot program intended to address the risks when targeted cancer treatments are approved without a companion diagnostic.

FDA

The FDA has expanded the label of Regeneron’s blockbuster eye therapy Eylea (aflibercept), allowing the administration of a higher 8-mg dose at up to 16-week intervals, the company announced Friday.

Roche

The combination of Roche’s Tecentriq (atezolizumab) and Exelixis’ Cabometyx (cabozantinib) met one of the primary endpoints in the pivotal Phase III CONTACT-02 trial, significantly improving progression-free survival in patients with metastatic castration-resistant prostate cancer, according to interim data released Monday by the companies.

Gilead Sciences said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company scrapped a late-stage trial due to efficacy concerns.

Boehringer Ingelheim

The company said the drug showed up to 19% weight loss after 46 weeks in a mid-stage trial.